Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-29
2006-08-29
Kemmerer, Elizabeth (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100
Reexamination Certificate
active
07098184
ABSTRACT:
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+T-cells using the ligands or fragments thereof.
REFERENCES:
patent: 4032635 (1977-06-01), Umezawa et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5376367 (1994-12-01), Williams
patent: 5457035 (1995-10-01), Baum et al.
patent: 5578707 (1996-11-01), Novick et al.
patent: 5821332 (1998-10-01), Godfrey et al.
patent: 6156878 (2000-12-01), Godfrey et al.
patent: 6242566 (2001-06-01), Godfrey et al.
patent: 6277962 (2001-08-01), Godfrey et al.
patent: 6333035 (2001-12-01), Sugamura et al.
patent: 6528055 (2003-03-01), Godfrey et al.
patent: 6528623 (2003-03-01), Godfrey et al.
patent: 2001/0044522 (2001-11-01), Godfrey et al.
patent: 2001/0044523 (2001-11-01), Godfrey et al.
patent: 2002/0077460 (2002-06-01), Godfrey et al.
patent: WO 90/15076 (1990-12-01), None
patent: WO 92/11870 (1992-07-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 95/12673 (1995-05-01), None
patent: WO 95/21251 (1995-08-01), None
patent: WO 95/21915 (1995-08-01), None
Aversa, G. et al., “A8.15 ‘Activation panel antigen expression on PBL activated by PHA or in MLR’”Leucocyte Typing IV. White Cell differentiation Antigens, W. Knapp et al., Oxford , GB: Oxford University Press pp. 498-501 (1989).
Baum et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34”EMBO Journal13(17) :3992-4001 (1994).
Bazan, F., “Emerging Families of Cytokines and Receptors.”Current Biology3(9) :603-606 (1993).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990).
Dijikstra, C. et al., “Multiple sclerosis: some possible therapeutic opportunities”Tips14:124-129 (1993).
Dorken et al., “Leukocyte Typing IV. White cell differentiation antigens, pp. 391, 396, 398, 409, 461, 474, 475, 477, 482, 485, 487, 488, 496, 501, 504”, W. Knapp, Oxford U. Press (1989).
Dunlap, N. et al., “A8.9 Expression of activation antigens on HTLV-I and HTLV-II cell lines”Leucocyte Typing IV. White Cell Differentiation antigens, W. Knapp et al., Oxford, GB: Oxford University Press pp. 487-488 (1989).
Flanagan, “The kit ligand: a cell surface molecule altered in steel mutant fibroblasts”Cell63:185-194 (1990).
Fraser et al., “Ligand-induced association between the T-cell antigen receptor and two glycoproteins”Proc. Natl. Acad. Sci. USA86:7133-7137 (1989).
Godfrey et al., “Molecular cloning of a cDNA encoding the human homolog of the rat OX-40 antigen”Tissue Antigens(Abstract AA057) 42(4) :253 (Oct. 1993).
Godfrey, W. et al., “Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor”J. Experimental Medicine180(2) :757-762 (Aug. 1994).
Godfrey, W. et al., “Stan-40, a new member of the FAS-TNFr superfamily expressed selectively on activated, human CD4+ T cells”J. Cellular Biochemistry, Supplement0(18D) :355 (1994).
Hamilton-Dutoit et al., “A8.3 ‘An immunohistological analysis of the mAb in the activation antigen panel’”Leucocyte Typing IV. White Cell Differentiation Antigens, W. Knapp et al., Oxford, GB:Oxford University Press pp. 475-476 (1989).
Imura et al., “The Human OX40/gp34 System Directly Mediates Adhesion of Activated T Cells to Vascular Edothelial Cells”Journal of Experimental Medicine183(5):2185-2195 (1996).
Karasuyama et al., “The proteins encoded by the VpreB and λ5 Pre-B cell-specific genes can associate with each other and with μ heavy chain”J. Expo. Med.172:969-972 (1990).
King, P. et al., “A8.17 ‘Tonsillar dendritic-cell-induced T-lymphocyte proliferation: analysis of molecular mechanisms using the activation panel of mAb’”Leucocyte Typing IV. White Cell Differentiation Antigens, W. Knapp et al., 1989:Oxford University Press pp. 503-505 (1989).
Kondo et al., “Sharing of the interleukin-2 (IL-2) receptor λ chain between receptors for IL-2 and IL-4”Science262:1874-1877 (1993).
Latza, U. et al., “The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen”European J. of Immunology24(3) :677-683 (Mar. 1994).
Mallet et al., “A new superfamily of cell surface proteins related to the nerve growth factor receptor”Immunology Today12:220-223 (1990).
Mallet et al., “Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes—A Molecule Related to Nerve Growth Factor Receptor.”EMBO Journal9(4) :1063-1068 (1990).
Marston, “The purification of eukaryotic polypeptides synthesized inEscherichia coli” Biochemical Journal240:1-12 (1986).
Mehra et al., “Efficient mapping of protein antigenic determinants”Proc. Natl. Acad. Sci. USA83:7013-7017 (1986).
Miura et al., “Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax”Molecular&Cellular Biology11(3):1313-1325 (1991).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”The Protein Folding Problem and Tertiary Structure Prediction, Merz & Le Grand, Boston:Birkhauser pp. 491-495 (1994).
Paterson et al., “Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr., detected only on CD4 positive T blasts”Molecular Immunology24:1281-1290 (1987).
Picker et al., “Control of lymphocyte recirculation in man. 1. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition”J. of Immunology150(3):1105-1121 (1993).
Picker et al., “Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells”J. of Immunology150(3):1122-1136 (1993).
Rentrop, O. et al., “A8.2 ‘Biochemical analysis of the Workshop antibodies of the activation section’”Leucocyte Typing IV. White Cell Differentiation Antigens, W. Knapp et al., Oxford, GB:Oxford University press pp. 473-474 (1989).
Schulman et al., “A better cell line for making hybridomas secreting specific antibodies”Nature276:269-270 (1978).
Slaviadis, T. et al., “Characterization of major peptides in Creutzfeldt-Jakob disease and scrapie”Proc. Natl. Acad. Sci. USA83: 6146-6150 (1986).
Tanaka et al., “A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-1)”Int. J. Cancer36:549-555 (1985).
Tateno et al., “Rat lymphoid cell lines withhuman T-cell leukemia virus production”Journal of Experimental Medicine159:1105-1116 (1984).
Tozawa et al., “Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I)”Int. J. Cancer42:231-238 (1988).
Vilella, R. et al., “A8.14 ‘Sequential appearance of the activation antigens’”Leucocyte Typing IV. White Cell Differentiation Antigens, W. Knapp et al., Oxford, GB:Oxford University Press pp. 495-498 (1989).
Engleman Edgar G.
Godfrey Wayne
Jones Day
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Method of treating rheumatoid arthritis and multiple... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating rheumatoid arthritis and multiple..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating rheumatoid arthritis and multiple... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610522